An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Portrazza

Chemical Namenecitumumab
Dosage FormInjection (intravenous; 800 mg/50 mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyEli Lilly and Company
Approval Year2015

Indication

  • In combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Portrazza (necitumumab) Prescribing Information2015Lilly USA, LLC, Indianapolis, IN
Document TitleYearSource
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.2016NICE
Document TitleYearSource
First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.2018Journal of Thoracic Disease